Printer Friendly

DR. Y.H. (MICHAEL) PAO RESIGNS AS DIRECTOR AT FLOW INTERNATIONAL CORP.

DR. Y.H. (MICHAEL) PAO RESIGNS AS DIRECTOR AT FLOW INTERNATIONAL CORP.
 KENT, Wash., April 7 /PRNewswire/ -- Lloyd J. Andrews, chairman of Flow International Corp. (NASDAQ: FLOW) today announced the resignation of Dr. Y.H. (Michael) Pao from the company's board of directors.
 "Dr. Pao has made significant contributions to FLOW's success during the past several years," Andrews said. "The transition to a new management team is now complete, and Dr. Pao has expressed his desire to pursue other interests. We are very grateful for his many contributions."
 In connection with Pao's resignation, FLOW's board of directors authorized a one-year extension of the note payable by Flow Industries Inc. to Flow International Corp. The note becomes due and payable at the earlier of either January 1994, or the market price of FLOW stock exceeding $9.50 per share.
 Flow International Corp. is the world's leading manufacturer of ultrahigh-pressure waterjets for industrial cutting, cleaning and HydroMilling(R) services.
 -0- 4/7/92
 /CONTACT: Thomas A. Cross of Flow International, 800-645-6992, or 206-872-3286; Susan McAllister of The Rockey Company, 206-728-1100, for Flow International/
 (FLOW) CO: Flow International Corp. ST: Washington IN: SU: PER


LM-JH -- SE001 -- 5699 04/07/92 09:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:200
Previous Article:CTI SIGNS LETTER OF INTENT FOR ACQUISITION AND FINANCING
Next Article:CONSILIUM CREATES NEW ORGANIZATIONAL STRUCTURE


Related Articles
FLOW INTERNATIONAL RECEIVES PAYMENT ON FLOW INDUSTRIES NOTE
AMDL ADDS TAIWAN DISTRIBUTOR TO INTERNATIONAL DISTRIBUTION AND MARKETING NETWORK
Names in the NEWS.
Index Distinguishes Cause of Dyspnea.
Nuvelo Announces Phase 1 Alfimeprase Results Presented at the AIM Symposium; Nuvelo to Webcast the Phase 1 Data at a Meeting for the Financial...
Supertex Schedules Third Fiscal Quarter Earning Release and Conference Call.
Supertex Schedules Third Fiscal Quarter Earning Release and Conference Call.
Nuvelo Announces the Completion of Its Phase 2 Alfimeprase Trial in Acute Peripheral Arterial Occlusion.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters